Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
Bristol Myers Forecasts 2025 Revenue Below Estimates After Strong Quarter
The company forecast 2025 revenue of around $45.5 billion, down from $48.3 billion in 2024 and below analyst expectations of $47.4 billion, according to LSEG data. It forecast 2025 earnings in the ...
Nasdaq15d
Bristol Myers Squibb Receives Positive CHMP Opinion For Opdivo + Yervoy In HCC
In the CheckMate -9DW trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) showed a median OS of 23.7 months compared to 20.6 months for the investigator's choice of lenvatinib or ...
Business Insider15d
Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy
Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the first-line ...
Cure Today17d
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
Opdivo plus Yervoy significantly improved PFS in MSI-H/dMMR metastatic CRC compared to Opdivo alone, with sustained separation of PFS curves. The combination therapy showed higher ORR and complete ...
Sports Illustrated25d
Super Bowl Logos Through the Years: A Look at How They’ve Evolved
Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...
Cure Today26d
The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...